13F-HR: Johnson & Johnson Discloses Q3 2025 Equity Holdings

Johnson & Johnson filed its Form 13F-HR, revealing its equity holdings totaling over $503 million as of September 30, 2025.

Summary

• Johnson & Johnson (J&J) filed its quarterly Form 13F-HR, detailing its institutional investment holdings for the period.
• The report covers the calendar quarter ended September 30, 2025.
• The total fair market value of the reported holdings is $503,699,862.
• The filing includes 20 distinct equity positions across various biotechnology and pharmaceutical companies.
• Johnson & Johnson Innovation JJDC, Inc. is listed as an included manager, consolidating its holdings within this report.
• All reported holdings indicate 'Defined' investment discretion and 'Sole' voting authority.

Sentiment

Score: 5

Explanation: The filing is a routine disclosure of institutional holdings, providing factual information without expressing explicit positive or negative sentiment regarding the filing entity's performance. The sentiment is neutral as expected for this type of regulatory report.

Positives

• The disclosure provides transparency into Johnson & Johnson's strategic investments in the healthcare and life sciences sectors, aligning with its core business focus on innovation.
• The portfolio's composition, featuring a range of biotech and pharmaceutical companies, indicates an active investment strategy aimed at fostering innovation and potentially identifying future growth areas.

Negatives

• NA

Risks

• The portfolio's concentration in the biotechnology and pharmaceutical sectors exposes it to industry-specific risks, including regulatory changes, clinical trial failures, and intense competition.
• Investments in smaller, often development-stage companies, as seen in the listed holdings, inherently carry higher risk and volatility compared to more established assets.
• Market fluctuations could lead to significant changes in the value of these equity holdings, impacting the overall portfolio performance.

Future Outlook

NA

Management Comments

• The person signing the report is authorized to submit it, that all information contained herein is true, correct and complete, and that it is understood that all required items, statements, schedules, lists, and tables, are considered integral parts of this form.

Industry Context

This Form 13F-HR filing provides transparency into Johnson & Johnson's equity investment portfolio, primarily through its venture capital arm, Johnson & Johnson Innovation JJDC, Inc. Such disclosures are common for large institutional investors and offer insights into their strategic investment focus within the broader healthcare and life sciences industries, often targeting innovative early-stage companies.

Comparison to Industry Standards

• Without specific benchmarks for Johnson & Johnson's venture arm or comparable institutional portfolios, a detailed assessment is not possible from this filing alone. However, the portfolio appears diversified across various biotech and pharma sub-sectors, which is a common strategy for venture capital arms in the life sciences industry.

Related Party Transactions

• Johnson & Johnson Innovation JJDC, Inc. is listed as an 'Other Included Manager,' indicating a related entity whose holdings are consolidated in this report.

Stakeholder Impact

• Shareholders: Provides transparency into Johnson & Johnson's investment strategy and the composition of a portion of its asset base, which can inform their assessment of the company's strategic direction and risk exposure.
• Investment Professionals: Offers insights into Johnson & Johnson's investment preferences and potential future partners or acquisition targets within the biotech and pharma sectors.
• Regulatory Authorities: Fulfills SEC disclosure requirements for institutional investment managers.

Next Steps

• NA

Key Dates

Keywords

Johnson & Johnson, 13F-HR, institutional holdings, equity investments, biotechnology, pharmaceuticals, healthcare, portfolio disclosure, JJDC